共查询到20条相似文献,搜索用时 140 毫秒
1.
Tsung-Hsien Lee Chung-Hsien Liu Chun-Chia Huang Kung-Chen Hsieh Pi-Mei Lin Maw-Sheng Lee 《Reproductive biology and endocrinology : RB&E》2009,7(1):100-10
Background
This study was designed to assess the capability of ovarian reserve markers, including baseline FSH levels, baseline anti-Müllerian hormone (AMH) levels, and antral follicle count (AFC), as predictors of live births during IVF cycles, especially for infertile couples with advanced maternal age and/or male factors. 相似文献2.
3.
Philippe Lehert Joan C Schertz Diego Ezcurra 《Reproductive biology and endocrinology : RB&E》2010,8(1):112
Background
Human menopausal gonadotrophins and recombinant human follicle stimulating hormone are the two main gonadotrophin products utilized for controlled ovarian stimulation in assisted reproductive technologies. In this meta-analysis, the number of oocytes was designated as the most relevant endpoint directly resulting from ovarian stimulation, and therefore where the drug effect may be estimated with the best sensitivity. 相似文献4.
5.
Stefania A Nottola Sandra Cecconi Serena Bianchi Cecilia Motta Gianna Rossi Maria A Continenza Guido Macchiarelli 《Reproductive biology and endocrinology : RB&E》2011,9(1):3
Background
In vitro maturation of ovarian follicles, in combination with cryopreservation, might be a valuable method for preserving and/or restoring fertility in mammals with impaired reproductive function. Several culture systems capable of sustaining mammalian follicle growth in vitro have been developed and many studies exist on factors influencing the development of in vitro grown oocytes. However, a very few reports concern the ultrastructural morphology of in vitro grown follicles. 相似文献6.
7.
Janet Kwee Mariet E Elting Roel Schats Joseph McDonnell Cornelis B Lambalk 《Reproductive biology and endocrinology : RB&E》2007,5(1):9-10
Background
The current study was designed to compare antral follicle count (AFC) and basal ovarian volume (BOV), the exogenous FSH ovarian reserve test (EFORT) and the clomiphene citrate challenge test (CCCT), with respect to their ability to predict poor and hyper responders. 相似文献8.
Induction of follicle stimulating hormone receptor in the granulosa cells of intact immature rat ovary by diethylstilbesterol,
an estrogen, has been studied.
A single injection of 4 mg of diethylstilbesterol produced 72 h later a 3-fold increase in follicle stimulating hormone receptor
concentration as monitored by [125I]-oFSH binding to isolated cells. The newly induced receptors were kinetically indistinguishable from the preexisting ones, as
determined by Lineweaver-Burk plot of the binding data. The induced receptors were functional as evidenced by increased ability
of the granulosa cells to incorporate [3H]-leucine into cellular proteins.
Neutralization of endogenous follicle stimulating hormone and luteinizing hormone by administering specific antisera had no
effect on the ability of diethylstilbesterol to induce follicle stimulating hormone receptors, whereas blockade of endogenous
prolactin secretion by ergobromocryptin administration significantly inhibited (∼ 30 %) the response to diethylstilbesterol;
this inhibition could be completely relieved by ovine prolactin treatment. However, ovine prolactin at the dose tried did
not by itself enhance follicle stimulating hormone receptor level.
Administration of ergobromocryptin to adult cycling rats at noon of proestrus brought about as measured on diestrusII, (a) a reduction of both follicle stimulating hormone (∼ 30 %) and luteinizing hormone (∼ 45 %) receptor concentration in granulosa
cells, (b) a drastic reduction in the ovarian tissue estradiol with no change in tissue progesterone and (c) reduction in
the ability of isolated granulosa cells to convert testosterone to estradiol in response to follicle stimulating hormone.
Ergobromocryptin treatment affected only prolactin and not follicle stimulating hormone or luteinizing hormone surges on the
proestrus evening. Treatment of rats with ergobromocryptin at proestrus noon followed by an injection of ovine prolactin (1
mg) at 1700 h of the same day completely reversed the ergobromocryptin induced reduction in ovarian tissue estradiol as well
as the aromatase activity of the granulosa cells on diestrus II, thus suggesting a role for proestrus prolactin surge in the
follicular maturation process 相似文献
9.
John A Luckenbach Dimitar B Iliev Frederick W Goetz Penny Swanson 《Reproductive biology and endocrinology : RB&E》2008,6(1):2
Background
The aim of this study was to identify differentially expressed ovarian genes during primary and early secondary oocyte growth in coho salmon, a semelparous teleost that exhibits synchronous follicle development. 相似文献10.
11.
12.
Background
In the Drosophila ovary, germ-line and soma cells are interconnected via gap junctions. The main gap-junction proteins in invertebrates are members of the innexin family. In order to reveal the role that innexins play in cell-cell communication during oogenesis, we investigated the localization of innexins 1, 2, 3 and 4 using immunohistochemistry, and analyzed follicle development following channel blockade. 相似文献13.
Qi Li Ling Shen Tianchi Xin Wenjuan Xiang Wenlian Chen Yin Gao Mingwei Zhu Lingzhu Yu Mingfa Li 《BMC developmental biology》2009,9(1):60
Background
Proper patterning of the follicle cell epithelium over the egg chamber is essential for the Drosophila egg development. Differentiation of the epithelium into several distinct cell types along the anterior-posterior axis requires coordinated activities of multiple signaling pathways. Previously, we reported that lethal(2)giant larvae (lgl), a Drosophila tumor suppressor gene, is required in the follicle cells for the posterior follicle cell (PFC) fate induction at mid-oogenesis. Here we explore the role of another two tumor suppressor genes, scribble (scrib) and discs large (dlg), in the epithelial patterning. 相似文献14.
Human follicle stimulating hormone is a pituitary glycoprotein that is essential for the maintenance of ovarian follicle development and testicular spermatogenesis. Like other members of the glycoprotein hormone family, it contains a common a subunit and a hormone specific subunit. Each subunit contains two glycosylation sites. The specific structures of the oligosaccharides of human follicle stimulating hormone have been shown to influence both thein vitro andin vivo bioactivity. Since the carbohydrate structure of a protein reflects the glycosylation apparatus of the host cells in which the protein is expressed, we examined the isoform profiles,in vitro bioactivity and metabolic clearance of a preparation of purified recombinant human follicle stimulating hormone derived from a stable, transfected Sp2/0 myeloma cell line, and pituitary human follicle stimulating hormone. Isoelectric focussing and chromatofocussing studies of human follicle stimulating hormone preparations both showed a more basic isoform profile for the recombinant human follicle stimulating hormone compared to that of pituitary human follicle stimulating hormone. The recombinant human follicle stimulating hormone had a significantly higher radioreceptor activity compared to that of pituitary human follicle stimulating hormone, consistent with a greaterin vitro potency. Pharmacokinetic studies in rats indicated a similar terminal half life (124 min) to that of the pituitary human follicle stimulating hormone (119 min). Preliminary carbohydrate analysis showed recombinant human follicle stimulating hormone to contain high mannose and/or hybrid type, in addition to complex type carbohydrate chains, terminating with both2,3 and2,6 linked sialic acids. These results demonstrate that recombinant human follicle stimulating hormone made in the Sp2/0 myeloma cells is sialylated, has a more basic isoform profile, and has a greaterin vitro biological potency compared to those of the pituitary human follicle stimulating hormone. 相似文献
15.
16.
Geoffrey H Trew Adam P Brown Samantha Gillard Stuart Blackmore Christine Clewlow Paul O'Donohoe Radoslaw Wasiak 《Reproductive biology and endocrinology : RB&E》2010,8(1):137
Background
Previous studies have reported conflicting results for the comparative doses of recombinant follicle stimulating hormone (rFSH) and highly purified human menopausal gonadotrophin (hMG-HP) required per cycle of in vitro fertilisation (IVF); the aim of this study was to determine the average total usage of rFSH versus hMG-HP in a 'real-world' setting using routine clinical practice. 相似文献17.
18.
19.
Stephanie Morgan Federica Lopes Charlie Gourley Richard A. Anderson Norah Spears 《PloS one》2013,8(7)
Purpose
Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature ovarian failure; the exact mechanism by which this occurs is uncertain. Here, two commonly used chemotherapeutic agents (cisplatin and doxorubicin) were added to a mouse ovary culture system, to compare the sequence of events that leads to germ cell loss. The ability of imatinib mesylate to protect the ovary against cisplatin or doxorubicin-induced ovarian damage was also examined.Experimental design
Newborn mouse ovaries were cultured for a total of six days, exposed to a chemotherapeutic agent on the second day: this allowed for the examination of the earliest stages of follicle development. Cleaved PARP and TUNEL were used to assess apoptosis following drug treatment. Imatinib was added to cultures with cisplatin and doxorubicin to determine any protective effect.Results
Histological analysis of ovaries treated with cisplatin showed oocyte-specific damage; in comparison doxorubicin preferentially caused damage to the granulosa cells. Cleaved PARP expression significantly increased for cisplatin (16 fold, p<0.001) and doxorubicin (3 fold, p<0.01). TUNEL staining gave little evidence of primordial follicle damage with either drug. Imatinib had a significant protective effect against cisplatin-induced follicle damage (p<0.01) but not against doxorubicin treatment.Conclusion
Cisplatin and doxorubicin both induced ovarian damage, but in a markedly different pattern, with imatinib protecting the ovary against damage by cisplatin but not doxorubicin. Any treatment designed to block the effects of chemotherapeutic agents on the ovary may need to be specific to the drug(s) the patient is exposed to. 相似文献20.
Veronica Rey-Ares Nikolai Lazarov Dieter Berg Ulrike Berg Lars Kunz Artur Mayerhofer 《Reproductive biology and endocrinology : RB&E》2007,5(1):40-10